Drug Trial Radar · NCT01248104
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
Last checked: Nov 20, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Mar 2010
Primary completion
Mar 2013
Study completion Feb 2015
Sponsor
- Lead sponsor
- Loma Linda UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
We designed a prospective double-blinded randomized trial in an attempt to detect a difference between tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in reducing transfusion in patients undergoing cardiac surgery.
Conditions
- Cardiopulmonary Bypass
Interventions
Tranexamic AcidDrug
Infusion during cardiac surgery
Aminocaproic AcidDrug
Infusion during cardiac surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Transfusion AmountsTime frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Loma Linda University Medical Center
Loma Linda, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.